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Inventing the Skin You Love to Test 
Rick Weiss 
 
Wanting nothing more than to darken her eyelashes, "Mrs. Brown went blind in the spring of 1933. She 
suffered constant pain for three months until her corneas peeled away, all for using an eyelash dye that 
promised to "radiate personality.” Her experience earned her a place in a chamber-of-horrors exhibit 
presented to Congress by the fledgling Food and Drug Administration as part of a successful campaign to 
pass the Food, Drug and Cosmetic Act of 1938. 
Countless such tragedies have no doubt been averted since the FDA gained, through that act, the 
authority to prohibit the sale of harmful cosmetics. But the legacy of "Mrs. Brown” (as she is referred to in 
FDA archives) remains a painful one for more than 100,000 rabbits each year that are subjected to similar 
fates under the act's provisions requiring toxicology tests on animals. 
Here is what happens, for example, in the classic Draize test for ocular irritancy. The rabbits are removed 
from their cages and held firmly while their eyelids are pulled back and a measured dose of a suspected 
eye irritant is squirted onto the eye. The rabbits' eyes are then observed after 24, 48 and 72 hours for 
redness, blistering, bleeding or blindness.    
In recent years, however, there has emerged a movement aimed at replacing such animal tests with in 
vitro, or test-tube, alternatives. More than 100 in vitro toxicology tests, most using cell or tissue cultures, 
are under development by scientists, including leading researchers in some of the largest household 
chemical and cosmetic companies. 
Replacing animal tests used to be considered a flakey, humane idea,” says Henry Spira, a leading 
spokesman for the movement against animal testing. But today, he says, “in vitro has moved into the 
mainstream. 
The problem now, some researchers and activists say, is that federal regulatory agencies are failing to 
provide the leadership and incentives needed to nurture this toxicological transition. Federal agencies 
have committees looking into the value of in vitro methods, but Spira says people “get bored, with 
committees after a while.” 
Spira knows how to break up such boredom. In one of the turning points of the animal-rights movement, 
he organized a highly successful 1980 protest against RevIon, Inc., the cosmetics industry "flagship.” 
Individuals from more than 400 groups dressed in rabbit costumes and marched outside RevIon's 
corporate offices in opposition to the company's use of the Draize test. Spira ran full-page newspaper ads 
depicting bandaged white rabbits asking, "How many rabbits does Revlon blind for beauty's sake?" 
Six months later Revlon initiated a research program at Rockefeller University in New York City to look for 
alternatives to the Draize test. Within months, other cosmetic companies contributed hundreds of 
thousands of dollars to similar programs, and the search for in vitro alternatives got seriously under way. 
Cheaper and Better 
Today cosmetic companies widely publicize their commitment to reduce the number of animals used in 
testing their products. Such commitments are more than token gestures; companies are finding that in 
vitro tests can have a number of advantages over traditional animal tests. According to the congressional 
Office of Technology Assessment, in vitro tests cost an average of $50,000 per product as opposed to 
$500,000 when animals are used. Moreover, in vitro tests can be more precise than many animal tests, 
making it possible to learn more about the molecular mechanisms that underlie inflammation, membrane 
damage and tissue toxicity. Such findings may lead to new strategies for the prevention or treatment of 
tissue injury. 
Membrane damage is one of the early signs of tissue toxicity, and evidence of it is sought in a number of 
in vitro tests. The so-called Neutral Red Uptake test, for example, uses a biological stain to look for 
evidence of membrane damage in culture-grown human skin cells. Similarly, a test being developed at 
the Medical College of Pennsylvania in Philadelphia exposes cultured dog kidney cells to a suspected 
toxin, then looks for increased permeability to a fluoroscein dye due to membrane damage. In a related 
test under investigation by researchers at the Colgate-Palmolive Co. and others, a small piece of egg 
shell is removed from a chick egg, leaving the heavily vascularized, underlying membrane intact. A few 
drops of a suspected toxin, dissolved in saline, are placed on the exposed membrane and the amount of 
blood vessel breakdown is taken as a measure of toxicity. 
Other in vitro tests are more specific. Researchers at Ohio State University are using sensitive, enzyme-
based antibody tests to detect the production of a substance called C-reactive protein in white blood cells 
grown in culture with liver cells. C-reactive protein is an early indicator of tissue damage and a key 
element in the inflammatory response. And recent progress in molecular biology is allowing researchers 
to measure miniscule amounts of messenger RNA (mRNA), indicative of the production of telltale proteins 
in damaged cells. 
"With the complexities of this [protein synthesis] system, many of us who were interested in the bio-
medicine end have almost by necessity become molecular biologists,” says Gerald Lazarus, of the 
University of Pennsylvania. Although it is a complicated area of investigation, he says, "We've gotten into 
this area because it gives us very crisp, critical and specific information, eliminating many of the problems 
inherent in biochemical studies.” 
There are disadvantages, however, to such specific measures of toxicity. Indeed, a fundamental problem 
with in vitro models is that they fail to mimic the complexity of the whole, living organism. Thus the 
premier caveat among in vitro toxicologists: Never settle for the results of a single test. 
Any risk measurement of human ocular irritation or any other type of toxicity is going to have to be based 
on a spectrum of data generated from a battery of tests,” says John Frazier, a professor of environmental 
health at Johns Hopkins University and associate director of the university's Center for Alternatives to 
Animal Testing (CAAT).  
Table-Sized Tissues 
In a broader approach to the problem, some researchers are seeking to combine the various components 
of skin into a living laboratory specimen that can be tested as a unit. Eugene Bell, professor emeritus at 
the Massachusetts Institute of Technology and chairman of Organogenesis, Inc., a biotechnology 
company in Cambridge, Mass, recently unveiled a "living skin equivalent" especially adapted for 
toxicology testing and expects to make it commercially available within 12 months. It is, in essence, a 
glob of living skin that can be painlessly exposed to various irritants. 
Developed by Organogenesis as a skin graft for the treatment of burns, the “test” skin,” Bell says, can be 
grown in sheets the size of conference tables. It has a synthetic skeleton and circulatory system, but is 
covered with a living outer layer and “feels like a piece of skin,” he says. Pigment containing melanocytes 
can be added so that the skin can tan after exposure to sunlight, Bell adds, add "it even repairs itself 
when wounded.” 
Bell makes the test skin in a two stage process that he calls "a bottle-filling operation.” First, he mixes 
cultured dermal fibroblast cells with appropriate nutrients and other biological molecules, and pours them 
all into a mold. Over a period of a few days, this gel condenses into a “dermal equivalent,” or a mass of 
cells similar to the deeper layers of skin.  
Later, human keritinocytes—the type of cells that form the outer layer of skin—are cultured onto the 
dermal equivalent. They multiply and spontaneously organize themselves into a multilayered, 
differentiated epidermis within about four days. After three to four weeks, a complete basal lamina—a 
layer of specially arranged cells—is formed between the epidermis and dermis. The basal lamina, present 
in living akin but never before created in vitro, is believed to be an important region governing toxin 
penetration and the inflammatory response. 
Not everyone is sold on Bell's new product. Paul Wegener, of San Diego-based Clonetics Corp., a maker 
of cultured epithelial cells, says there may be advantages to testing different cell types separately. “And 
one thing you can tell about Bell's product,” he adds: "It's not going to be cheap.” 
But the successful modeling of a tissue system even hinting of the complexity of human skin bodes well 
for the future of in vitro testing. "l think that this is just the very beginning of a method to create hybrid 
organisms that will be useful for testing,” Bell says. "We are really primitives at this point.” 
If the goal is to become less primitive, and a decline in the use of animal tests is one measure of that 
goal, the progress is being made, according to Animal Rights International, a coalition of animal-rights 
groups in New York City. Independent toxicology labs, cosmetic company trade associations and 
government agencies all are exploring in vitro alternatives, and no fewer than five scientific journals 
devoted to in vitro methods me been born in the past two years. 
The Regulatory Bottleneck 
So far, however, regulatory agencies—the key link between basic research and commercial use—have 
given few clues about which, if any, in vitro tests may be accepted as alternatives to current tests. And 
although committees abound, says Kailash Gupta, of the health-sciences division of the Consumer 
Product Safety Commission. "None of the agencies, as far as I know, has seriously sat down and said 
that these are the criteria that alternative tests should meet to be accepted.” 
Indeed, says Spira in a recent letter to federal regulators, although "regulatory agencies have publicly 
stated their support for alternatives … most of the regulatory agencies' actions have sent quite a different 
message to the industry: that, for regulatory purposes, it seems impossible even to begin replacing 
traditional methods with alternatives.” 
Spira notes that the Environmental Protection Agency still refuses to accept a more humane version of 
the Draize test, the Low Volume Eye Irritation (LVEI) test, that be says has been studied for more than a 
decade and has been designated a standard method by the American Society for Testing and Materials. 
The EPA has also been criticized for continuing to require the so-called LD50 test as a measure of 
mammalian toxicity—a test described by internationally renowned toxicologist Gerhardt Zbinden as “a 
ritual mass execution of animals.” 
Theodore M. Farber, director of the EPA's toxicology branch, confirms that the LD50 is still required but 
says EPA has "formed a committee that will be looking for some acceptable alternatives” to it. EPA also is 
“actively looking at the Low Volume Eye Irritation test” and may validate alternatives for at least limited 
use as early as this spring or summer. 
Bureaucratic sluggishness is not the only factor slowing acceptance of in vitro alternatives. Difficult 
scientific hurdles remain, and uppermost among them is the need to design objective validation criteria for 
new test methods. For example, to test the validity of two new in vitro tests that make use of different 
tissue cultures each culture might be exposed to standardized selection of common irritants—from the 
most innocuous to the most corrosive—and the results compared to traditional animal-test results. But 
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